| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1,4 M € | — | — | — | — | 1,4 M € | — | — | — | — | — | 30,0 k € | — | |||||||||||||
| Gross margin | 387,5 k € | +335.4% | 89,0 k € | -47.0% | 167,8 k € | +108.8% | -1,9 M € | -13364.9% | 14,4 k € | -95.0% | 290,4 k € | +124.7% | -1,2 M € | -777.4% | -134,0 k € | -410.2% | 43,2 k € | +817.4% | 4,7 k € | +111.1% | -42,4 k € | -614.8% | 8,2 k € | +282.0% | -4,5 k € | |
| EBITDA | -1,2 M € | +18.7% | -1,5 M € | -0.2% | -1,4 M € | +64.2% | -4,0 M € | -107.6% | -1,9 M € | -83.7% | -1,1 M € | +30.2% | -1,5 M € | -273.2% | -407,3 k € | -204.9% | -133,6 k € | -141.2% | -55,4 k € | -29.7% | -42,7 k € | -634.9% | 8,0 k € | +266.9% | -4,8 k € | |
| Operating profit | -1,8 M € | +21.9% | -2,4 M € | +2.4% | -2,4 M € | +58.5% | -5,8 M € | -107.1% | -2,8 M € | -83.7% | -1,5 M € | +27.7% | -2,1 M € | -150.0% | -848,9 k € | -126.7% | -374,4 k € | -348.6% | -83,5 k € | -95.4% | -42,7 k € | -634.9% | 8,0 k € | +266.9% | -4,8 k € | |
| Profit/loss | -1,6 M € | +14.5% | -1,9 M € | +27.1% | -2,5 M € | +56.5% | -5,8 M € | -97.1% | -3,0 M € | -92.5% | -1,5 M € | +27.7% | -2,1 M € | -150.5% | -850,7 k € | -126.7% | -375,3 k € | -349.0% | -83,6 k € | -95.6% | -42,7 k € | -708.4% | 7,0 k € | +245.7% | -4,8 k € | |
| Equity | 15,9 M € | -9.1% | 17,5 M € | -9.6% | 19,3 M € | +940.3% | 1,9 M € | -75.9% | 7,7 M € | +169.1% | 2,9 M € | -64.9% | 8,2 M € | +329.9% | 1,9 M € | +131.6% | 819,1 k € | +84.3% | 444,5 k € | +2127.2% | -21,9 k € | -205.4% | 20,8 k € | +51.0% | 13,8 k € | |
| Total assets | 16,4 M € | -10.1% | 18,2 M € | -10.6% | 20,3 M € | +287.1% | 5,3 M € | -39.9% | 8,8 M € | +3.0% | 8,5 M € | -2.0% | 8,7 M € | +260.5% | 2,4 M € | +130.4% | 1,0 M € | +96.2% | 532,3 k € | +740.6% | 63,3 k € | +66.9% | 37,9 k € | +168.0% | 14,2 k € | |
| Cash | 69,3 k € | -42.4% | 120,4 k € | -24.4% | 159,3 k € | -68.9% | 512,3 k € | -9.3% | 565,1 k € | -85.0% | 3,8 M € | -51.6% | 7,8 M € | +400.3% | 1,5 M € | +276.8% | 411,3 k € | +75.3% | 234,6 k € | +1133.5% | 19,0 k € | +163.7% | 7,2 k € | -47.0% | 13,6 k € | |
| Debts | 405,2 k € | -33.3% | 607,4 k € | -26.2% | 822,7 k € | -73.9% | 3,2 M € | +337.8% | 719,8 k € | -86.0% | 5,2 M € | +895.3% | 518,1 k € | +2.1% | 507,6 k € | +125.5% | 225,1 k € | +156.9% | 87,6 k € | +2.8% | 85,2 k € | +397.0% | 17,1 k € | +4369.8% | 383,6 € | |
| Staff | 13,8 | 14 | 13,4 | 14 | 14 | 13 | 4,5 | 3,7 | 2,8 | 1 | — | — | — | |||||||||||||
Public limited company · Gent · incorporated on 29/12/2010 · 13,8 ETP
Public limited company loss-making in the latest fiscal year. Cash position declining (-42.4%).
Acceptable counterparty for a moderate engagement. Require 2 fiscal years of detailed accounts before any significant exposure. The abridged model hides revenue.
PharmaFluidics is a Public limited company incorporated in 2010. Its main activity is: Research and experimental development on natural sciences and engineering. Its registered office is in Gent. It employs on average 13,8 ETP workers (FTE).
Key indicators
7-day free trial, no credit card required.
7-day free trial, no credit card required.
7-day free trial, no credit card required.
Source: Belgian Official Gazette